BiomedicineNews.net

Biomedicine Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

The European Commission ( EC ) has granted marketing authorization for Breyanzi ( Lisocabtagene maraleucel; Liso-cel ), a CD19-directed chimeric antigen receptor ( CAR ) T cell immunotherapy, for the ...


The European Commission ( EC ) has approved Kymriah ( Tisagenlecleucel ), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory ( r/r ) follicular lymphoma ( FL ) after ...


Positive topline results from the RAISE trial evaluating investigational treatment Zilucoplan, a self-administered, subcutaneous ( SC ) peptide inhibitor of complement component 5 ( C5 inhibitor ), ve ...


The European Commission ( EC ) has granted marketing authorization for Breyanzi ( Lisocabtagene maraleucel; Liso-cel ), a CD19-directed chimeric antigen receptor ( CAR ) T cell immunotherapy, for the ...


Preclinical studies of COVID-19 mRNA vaccine BNT162b2, developed by Pfizer and BioNTech, have shown reversible hepatic effects in animals that received the BNT162b2 injection. A recent study has s ...


Cancer patients rarely die from the primary tumor but rather from the metastases, even after successful tumor surgery. This is because cancer cells sometimes spread to other parts of body early in the ...


Aromatic L-amino acid decarboxylase ( AADC ) deficiency is a rare genetic disorder characterized by deficient synthesis of dopamine and serotonin. It presents in early infancy, and causes severe devel ...


Regkirona is a medicine used for treating COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of their disease becoming severe. Regkirona contains the active subst ...


Ronapreve is a medicine used for treating COVID-19 in adults and adolescents ( from 12 years of age and weighing at least 40 kilograms ) who do not require supplemental Oxygen and who are at increased ...


The European Commission ( EC ) has granted Conditional Marketing Authorization for Abecma ( Idecabtagene vicleucel; Ide-cel ), a first-in-class B-cell maturation antigen ( BCMA )-directed chimeric ant ...


The FDA ( U.S. Food and Drug Administration ) has approved Abecma ( Idecabtagene vicleucel; Ide-cel ) as the first B-cell maturation antigen ( BCMA )-directed chimeric antigen receptor ( CAR ) T cell ...


The U.S. Food and Drug Administration ( FDA ) has granted accelerated approval to Yescarta ( Axicabtagene ciloleucel ) for the treatment of adult patients with relapsed or refractory follicular lympho ...


The U.S. Food and Drug Administration ( FDA ) has approved Breyanzi ( Lisocabtagene maraleucel; Liso-cel ), a CD19-directed chimeric antigen receptor ( CAR ) T cell therapy for the treatment of adult ...


The U.S. Food and Drug Administration ( FDA ) has granted accelerated approval to Tecartus ( Brexucabtagene autoleucel, formerly KTE-X19 ), the first and only approved chimeric antigen receptor ( CAR ...


Newborns face unique immunological challenges immediately after birth. As they depart a relatively sterile fetal environment, they are abruptly exposed to a multitude of foreign antigens, the major bu ...